Skip to main content Accessibility help
×
Home

Eliminating drug price differentials across government programmes in the USA

  • Kalipso Chalkidou (a1), Gerard F Anderson (a2) and Ruth Faden (a3)

Abstract

Federal agencies in the USA pay significantly different prices for the same prescription drugs because each agency uses a different approach to derive the payment rate. Because we do not identify any economic rationale or socially accepted moral reasoning that would justify the current level of price variation, we suggest that the federal government should pay a uniform price for each drug. Laws and regulations that give certain federal agencies the ability to earn rebates, use formularies, or permit other special arrangements would need to be eliminated in order to have a single payment rate. This could make some government agencies worse off than others; however, a uniform payment rate would not need to affect beneficiaries’ current financial contributions, access to drugs, benefits or overall public expenditures. At the same time, having a single rate would permit the government to adopt a more effective approach to purchasing drugs and send a consistent message to pharmaceutical companies concerning which types of drugs the government wants them to develop for government beneficiaries. How this single price would be derived and how it would compare with the lowest or highest prices currently achieved by government agencies would depend on a variety of policy issues including the government’s desire to encourage pharmaceutical research and development and the need to control health care spending.

Copyright

Corresponding author

Correspondence to: Dr Kalipso Chalkidou, Director, NICE International, National Institute for Health and Clinical Excellence, 71 High Holborn, London WC1 V 6NA, UK. Email: kalipso.chalkidou@nice.org.uk

References

Hide All
Anderson, G. F., Shea, D. G., Hussey, P. S., Keyhani, S.Zephyrin, L. (2004), ‘Doughnut holes and price controls’, Health Affairs (Millwood) Suppl Web Exclusives: W4-396-404.
Armstrong, M. (2006), ‘Recent developments in the economics of price discrimination’, in R. Blundell, W. K. Newey and T. Persson (eds), Advances in Economics and Econometrics: Theory and Applications: Ninth World Congress, volume II, Cambridge, UK: Cambridge University Press: 97141.
Atkinson, A. B. (1983), The Economics of Inequality, Oxford: Clarendon Press.
Beauchamp, T. L.Childress, J. F. (1994), Principles of Biomedical Ethics, 4th edition. New York: Oxford University Press.
Berenson, A. (2006), ‘As drug prices climb, democrats find fault with medicare plan’, The New York Times.
Brock, D. W. (2002), ‘Priority to the worse off in health-care resource prioritization’, in R. Rhodes, M. Battin and A. Silvers (eds), Medicine and Social Justice, Oxford: Oxford University Press: 362372.
Center for Medicare Advocacy (2008). Summary of Medicare Prescription Drug Plans.
Chalkidou, K., Tunis, S., Lopert, R., Rochaix, L., Sawicki, P. T., Nasser, M.Xerri, B. (2009), ‘Comparative effectiveness research and evidence-based health policy: experience from four countries’, The Milbank Quarterly, 87(2): 339367.
Cohen, F. J. (2005), ‘Macro trends in pharmaceutical innovation’, Nature Reviews. Drug Discovery, 4(1): 7884.
Congressional Budget Office (1996), How the Medicaid Rebate on Prescriptions Drugs Affects Pricing in the Pharmaceutical Industry. Washington, DC.
Congressional Budget Office (2005), Prices for Brand-Name Drugs Under Selected Federal Programs, Washington, DC.
Corts, K. S. (1998), ‘Third degree price discrimination in oligopoly: all-out competition and strategic commitment’, The RAND Journal of Economics, 29(2): 306323.
Daniels, N. (2008), Just Health: Meeting Health Needs Fairly, Cambridge: Cambridge University Press: 1128.
Danzon, P. M. (1997), ‘Price discrimination for pharmaceuticals: welfare effects in the US and the EU’, International Journal of the Economics of Business, 4(3): 301321.
Dasgupta, P.Stiglitz, J. (1980), ‘Uncertainty, industrial structure and the speed of R&D’, The Bell Journal of Economics, 11(1): 128.
Department of Health (2009), The 2009 Pharmaceutical Price Regulation Scheme, London.
Dorsey, E. R., Thompson, J. P., Carrasco, M., de Roulet, J., Vitticore, P., Nicholson, S., Johnston, S. C., Holloway, R. G.Moses, H. 3rd (2009), ‘Financing of US biomedical research and new drug approvals across therapeutic areas’, PLoS One, 4(9): e7015.
Duggan, M., Scott-Morton, F. (2005), The distortionary effects of government procurement: evidence from medicaid prescription drug purchasing. In Working paper.
Frank, R. G. (2001), ‘Prescription drug prices: why do some pay more than others do?’, Health Affairs (Millwood), 20(2): 115128.
Frank, R. G.Newhouse, J. P. (2008), ‘Should drug prices be negotiated under part D of Medicare? and if so, how?’, Health Affairs (Millwood), 27(1): 3343.
Frank, R.Newhouse, J. (2007), ‘Mending the medicare prescription drug benefit: improving consumer choices and restructuring purchasing’, in The Hamilton Project, Washington, DC: The Brookings Institution.
Gagnon, M. A.Lexchin, J. (2008), ‘The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States’, PLoS Medicine, 5(1): e1.
Galbraith, J. K. (1952), American Capitalism, The Concept of Countervailing Power, Boston: Houghton Mifflin.
Garber, A., Jones, C., Romer, P. 2006. Insurance and Incentives for Medical Innovation, NBER Working Paper.
Garber, A. M. (2004), ‘Cost-effectiveness and evidence evaluation as criteria for coverage policy’, Health Affairs (Millwood), Suppl Web Exclusives: W4-284-96.
Garber, A. M.McClellan, M. B. (2007), ‘Satisfaction guaranteed – “payment by results” for biologic agents’, The New England Journal of Medicine, 357(16): 15751577.
Ginsburg, P. B. (2003), ‘Can hospitals and physicians shift the effects of cuts in Medicare reimbursement to private payers?’, Health Affairs (Millwood), Suppl Web Exclusives: W3-472-9.
Gold, M. (1996), Cost-effectiveness in Health and Medicine, Washington, DC: Oxford University Press.
Gold, M. R., Sofaer, S.Siegelberg, T. (2007), ‘Medicare and cost-effectiveness analysis: time to ask the taxpayers’, Health Affairs (Millwood), 26(5): 13991406.
Government Accountability Office (1991), Medicaid: Changes in Drug Prices Paid by VA and DoD Since Enactment of Rebate Provisions, Washington, DC.
Government Accountability Office (1993), Changes in Drug Prices Paid by HMOs and Hospitals Since Enactment of Rebate Provisions, Washington, DC.
Government Accountability Office (2007), E Dicken Testimony Before the Committee on Finance, An Overview of Approaches to Negotiate Drug Prices used by Other Countries and US Private Payers and Federal Programs, Washington, DC: Committee on Finance.
Hausman, J.MacKie-Mason, J. (1988), ‘Price discrimination and patent policy’, The RAND Journal of Economics, 19(2): 253265.
Hogberg, D. (2007), ‘Letting Medicare “Negotiate” Drug Prices: Myths vs. Reality, National Center for Public Policy research 2007’, http://www.nationalcenter.org/NPA550MedicareDrugPrices.html [cited April 2008].
Holmes, T. (1989), ‘The effects of third degree price discrimination in oligopoly’, The American Economic Review, 79(1): 244250.
House Oversight Committee (2007), High Expenses and Low Rebates Increase the Costs of Medicare Drug Coverage, Washington, DC.
Jacobson, G (2007). Pharmaceutical Costs: A Comparison of VA, Medicaid and Medicare Policies, edited by Congressional Research Office, Washington, DC.
Kaiser Family Foundation (2007), Medicare part D 2008 data spotlight: Premiums.
Kyle, M. K.Ridley, D. B. (2007), ‘Would greater transparency and uniformity of health care prices benefit poor patients?’, Health Affairs (Millwood), 26(5): 13841391.
Light, D. W. (2009), ‘Global drug discovery: Europe is ahead’, Health Affairs (Millwood), 28(5): w969w977.
Lopert, R.Moon, M. (2007), ‘Toward a rational, value-based drug benefit for Medicare’, Health Affairs (Millwood), 26(6): 16661673.
Mooney, G. (1987), ‘What does equity in health mean? Qu’est-ce que l’equite en matiere de sante?’, World Health Statistics Quarterly. Rapport Trimestriel De Statistiques Sanitaires Mondiales, 40: 296303.
Morrisey, M. A. (2003), ‘Cost shifting: new myths, old confusion, and enduring reality’, Health Affairs (Millwood), Suppl Web Exclusives: W3-489-91.
Morrisey, M. A. (1996), Employee Benefit Research Institute issue brief.
New Molecular Entities slump continues: FDA clears 18 novel drugs in 2006, same as 2005. 2007. Pharmaceutical Approvals Monthly 12(1): 7–12.
Newhouse, J. P. (2004), ‘How much should Medicare pay for drugs?’, Health Affairs (Millwood), 23(1): 89102.
Omnibus Budget Reconciliation Act of 1990 OBRA-90, Pub.L. 101-508, 104 Stat. 1388. 1990-11-05.
Pharmaceutical Research and Manufacturers of America (2004). Industry Profile.
Pigou, A. C. (1920), The Economics of Welfare, London: Macmillan.
Poisal, J. A., Truffer, C., Smith, S., Sisko, A., Cowan, C., Keehan, S.Dickensheets, B. (2007), ‘Health spending projections through 2016: modest changes obscure part D’s impact’, Health Affairs (Millwood), 26(2): w242w253.
Pollard, M. R.Coster, J. M. (1991), ‘Savings for Medicaid drug spending’, Health Affairs (Millwood), 10(2): 196206.
Powers, M.Faden, R. (2000), ‘Inequalities in health, inequalities in health care: four generations of discussion about justice and cost-effectiveness analysis’, Kennedy Institute of Ethics Journal, 10(2): 109127.
Ramsey, F. P. (1927), ‘A contribution to the theory of taxation’, The Economic Journal, 37(145): 4761.
Reinhardt, U. E. (2001), ‘Perspectives on the pharmaceutical industry’, Health Affairs (Millwood), 20(5): 136149.
Reinhardt, U. E., Hussey, P. S.Anderson, G. F. (2004), ‘US health care spending in an international context’, Health Affairs (Millwood), 23(3): 1025.
Robinson, J. (1933), The Economics of Imperfect Competition, London: Macmillan.
Scherer, F. M. (1997), ‘How US antitrust can go astray: the brand name prescription drug litigation’, International Journal of the Economics of Business, 4(3): 239256.
Schmalensee, R. (1981), ‘Output and welfare implications of monopolistic third-degree price discrimination’, American Economic Review, 71(1): 242247.
Scott-Morton, F. (1997), ‘The strategic response by pharmaceutical firms to the Medicaid most-favoured-customer rules’, Rand Journal of Economics, 28(2): 269290.
Skinner, J. S., Staiger, D. O.Fisher, E. S. (2006), ‘Is technological change in medicine always worth it? the case of acute myocardial infarction’, Health Affairs (Millwood), 25(2): w34w47.
Tandon, P. (1983), ‘Rivalry and the excessive allocation of resources to research’, The Bell Journal of Economics, 14(1): 152165.
Tritz, K. (2005), A CRS Series on Medicaid: Dual Eligibles, edited by Congressional Research Service. Washington, DC: The Library of Congress.
Ubel, P. A. (2001), Pricing Life: Why It’s Time for Health Care Rationing, Cambridge, MA: The MIT Press.
United States District Court and District of Massachusetts. Pharmaceutical Industry Average Wholesale Price Litigation. In M.D.L. No. 1456, Civil Action No. 01-12257-PBS.
Veatch, R. M. (1999), Justice, the Basic Social Contract, and Health Care. Contemporary Issues in Bioethics, 5th edition. Belmont, CA: Wadsworth.
Waters, H. R. (2000), ‘Measuring equity in access to health care’, Social Science and Medicine, 51(4): 599612.

Eliminating drug price differentials across government programmes in the USA

  • Kalipso Chalkidou (a1), Gerard F Anderson (a2) and Ruth Faden (a3)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed